Comparing DC subsets in solid tumors: what about DC3s?

Area of Science:

• Immunology
• Cancer Biology
• Cellular Biology

Background:

• Dendritic cells (DCs) are crucial immune sentinels bridging innate and adaptive immunity.
• DCs are heterogeneous, with subsets like DC3 exhibiting unique roles in immune responses and disease.
• The tumor microenvironment (TME) contains DCs that can either promote anti-tumor immunity or facilitate immune evasion.

Purpose of the Study:

• To review the phenotypic, functional, and developmental diversity of DC subsets, with a focus on DC3s.
• To explore the specific contributions of DC3s to cancer within the TME.
• To highlight the immunomodulatory functions of DC3s for potential therapeutic applications.

Main Methods:

• Review of existing literature on dendritic cell subsets, focusing on DC3s.
• Analysis of DC phenotypes, functions, and ontogeny in the context of cancer.
• Correlation of DC3 presence with patient outcomes in various solid tumors.

Main Results:

• DC3s are distinct from other DC subsets (cDC1s, cDC2s, pDCs) and monocytes.
• DC3s prime T cells, promoting Th17 responses and CD8+ T cells with tissue-resident memory phenotypes.
• DC3 presence in tumors shows varied prognostic value: associated with better survival in pancreatic and oropharyngeal cancers, but immunosuppression in lung cancer and melanoma.

Conclusions:

• DC3s exhibit dynamic immunomodulatory functions within the tumor microenvironment.
• The role of DC3s in cancer is context-dependent, influencing patient outcomes differently across tumor types.
• Targeting DC3s offers potential for novel therapeutic strategies in cancer and immune disorders.